Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29264470 | 1.00 | DUT (0.53) | DUTP2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL20879422 | 1.00 | DUT (0.53) | DUTP2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL9279845 | 0.91 | P2RY6 (0.58) | DUTP2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL6913590 | 0.89 | DUT (0.47) | DUTP2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL1501001 | 0.89 | P2RY2 (0.61) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL22110865 | 0.89 | P2RY2 (0.61) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL661070 | 0.89 | P2RY2 (0.61) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL25711998 | 0.89 | P2RY2 (0.61) | P2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL14731558 | 0.89 | P2RY2 (0.55) | DUTP2RY6P2RY2P2RY4P2RY14 | |
| SCHEMBL5320623 | 0.88 | P2RY6 (0.49) | DUTP2RY6P2RY2P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4556010-A2 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | Emory University (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3750544-B1 | JAK INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF A VIRAL DISEASE CAUSED BY A CORONAVIRIDAE | UNIV EMORY (US) | 2025-03-05 | — | — | EP | disclosed |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2024-12-19 | — | — | US | disclosed |
| US-20240262857-A1 | NOVEL UNIVERSAL ANTI-RNA VIRUS AGENTS | EMORY UNIVERSITY | 2024-08-08 | — | — | US | disclosed |
| US-20240209428-A1 | Pyrophosphorolysis activated fluorescence to measure PAP amplification of nucleic acid | DING SHAOFENG (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | UNIV EMORY (US) | 2024-05-30 | — | — | US | disclosed |
| US-11969427-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | EMORY UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-11921049-B2 | Pyrophosphorolysis activated fluorescence to measure PAP amplification of nucleic acid | DING SHAOFENG (US) | 2024-03-05 | — | — | US | disclosed |
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| WO-2000043014-A2 | BETA-D-2',3'-DIDEHYDRO-2',3'-DIDEOXY-5-FLUOROCYTIDINE FOR USE IN THE TREATMENT OF HIV INFECTIONS | EMORY UNIVERSITY (US) | 2000-07-27 | — | — | WO | disclosed |
| US-6071922-A | PYRIMIDINE-BASE NUCLEOSIDES; VIRICIDES; HIV; HEPATITIS B VIRUS; AIDS-RELATED COMPLEX; IMMUNODEFICIENCY VIRUS IN ANIMALS AND HUMANS; ANTIPROLIFERATIVE AGENTS | EMORY UNIVERSITY (US) | 2000-06-06 | — | — | US | disclosed |
| WO-1999066936-A9 | USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV | UNIV EMORY (US) | 2000-04-06 | — | — | WO | disclosed |
| EP-0986375-A2 | USE OF MKC-442 IN COMBINATION WITH OTHER ANTIVIRAL AGENTS | Triangle Pharmaceuticals Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| EP-0970078-A1 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999066936-A1 | USE OF 3'-AZIDO-2',3'-DIDEOXYURIDINE IN COMBINATION WITH FURTHER ANTI-HIV DRUGS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HIV | EMORY UNIVERSITY (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999043691-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1998041522-A9 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | — | 1999-03-04 | — | — | WO | disclosed |
| WO-1998044913-A2 | COMPOSITIONS CONTAINING MKC-442 IN COMBINATION WITH OTHER ANTIVIRAL AGENTS | TRIANGLE PHARMACEUTICALS, INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998041522-A1 | SYNTHESIS, ANTI-HUMAN IMMUNODEFICIENCY VIRUS AND ANTI-HEPATITIS B VIRUS ACTIVITIES OF 1,3-OXASELENOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744831-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | DUT 36/4885P2RY6 736/4885P2RY2 776/4885 |
| US-20240415838-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | MERTK, PNP, HAVCR2 | DUT 123/4885P2RY6 104/4885P2RY2 143/4885 |
| US-11969427-B2 | Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection | MERTK, PNP, HAVCR2 | DUT 123/4885P2RY6 104/4885P2RY2 143/4885 |
| US-20240262857-A1 | NOVEL UNIVERSAL ANTI-RNA VIRUS AGENTS | NSUN2, RBM28, HNRNPC | DUT 120/4885P2RY6 3462/4885P2RY2 3773/4885 |
| US-20240173322-A1 | ANTIVIRAL JAK INHIBITORS USEFUL IN TREATING OR PREVENTING RETROVIRAL AND OTHER VIRAL INFECTIONS | JAK1, JAK3, PNP | DUT 35/4885P2RY6 689/4885P2RY2 880/4885 |
| US-12383558-B2 | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | JAK1, JAK3, PNP | DUT 35/4885P2RY6 689/4885P2RY2 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.